Cargando…

Immunogenic ferroptosis and where to find it?

Ferroptosis is a recently discovered form of regulated cell death that is morphologically, genetically, and biochemically distinct from apoptosis and necroptosis, and its potential use in anticancer therapy is emerging. The strong immunogenicity of (early) ferroptotic cancer cells broadens the curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Demuynck, Robin, Efimova, Iuliia, Naessens, Faye, Krysko, Dmitri V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671998/
https://www.ncbi.nlm.nih.gov/pubmed/34903554
http://dx.doi.org/10.1136/jitc-2021-003430
_version_ 1784615267448389632
author Demuynck, Robin
Efimova, Iuliia
Naessens, Faye
Krysko, Dmitri V
author_facet Demuynck, Robin
Efimova, Iuliia
Naessens, Faye
Krysko, Dmitri V
author_sort Demuynck, Robin
collection PubMed
description Ferroptosis is a recently discovered form of regulated cell death that is morphologically, genetically, and biochemically distinct from apoptosis and necroptosis, and its potential use in anticancer therapy is emerging. The strong immunogenicity of (early) ferroptotic cancer cells broadens the current concept of immunogenic cell death and opens up new possibilities for cancer treatment. In particular, induction of immunogenic ferroptosis could be beneficial for patients with cancers resistant to apoptosis and necroptosis. However, ferroptotic cancer cells may be a rich source of oxidized lipids, which contribute to decreased phagocytosis and antigen cross-presentation by dendritic cells and thus may favor tumor evasion. This could explain the non-immunogenicity of late ferroptotic cells. Besides the presence of lactate in the tumor microenvironment, acidification and hypoxia are essential factors promoting ferroptosis resistance and affecting its immunogenicity. Here, we critically discuss the crucial mediators controlling the immunogenicity of ferroptosis that modulate the induction of antitumor immunity. We emphasize that it will be necessary to also identify the tolerogenic (ie, immunosuppressive) nature of ferroptosis, which can lead to tumor evasion.
format Online
Article
Text
id pubmed-8671998
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86719982021-12-28 Immunogenic ferroptosis and where to find it? Demuynck, Robin Efimova, Iuliia Naessens, Faye Krysko, Dmitri V J Immunother Cancer Review Ferroptosis is a recently discovered form of regulated cell death that is morphologically, genetically, and biochemically distinct from apoptosis and necroptosis, and its potential use in anticancer therapy is emerging. The strong immunogenicity of (early) ferroptotic cancer cells broadens the current concept of immunogenic cell death and opens up new possibilities for cancer treatment. In particular, induction of immunogenic ferroptosis could be beneficial for patients with cancers resistant to apoptosis and necroptosis. However, ferroptotic cancer cells may be a rich source of oxidized lipids, which contribute to decreased phagocytosis and antigen cross-presentation by dendritic cells and thus may favor tumor evasion. This could explain the non-immunogenicity of late ferroptotic cells. Besides the presence of lactate in the tumor microenvironment, acidification and hypoxia are essential factors promoting ferroptosis resistance and affecting its immunogenicity. Here, we critically discuss the crucial mediators controlling the immunogenicity of ferroptosis that modulate the induction of antitumor immunity. We emphasize that it will be necessary to also identify the tolerogenic (ie, immunosuppressive) nature of ferroptosis, which can lead to tumor evasion. BMJ Publishing Group 2021-12-13 /pmc/articles/PMC8671998/ /pubmed/34903554 http://dx.doi.org/10.1136/jitc-2021-003430 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Demuynck, Robin
Efimova, Iuliia
Naessens, Faye
Krysko, Dmitri V
Immunogenic ferroptosis and where to find it?
title Immunogenic ferroptosis and where to find it?
title_full Immunogenic ferroptosis and where to find it?
title_fullStr Immunogenic ferroptosis and where to find it?
title_full_unstemmed Immunogenic ferroptosis and where to find it?
title_short Immunogenic ferroptosis and where to find it?
title_sort immunogenic ferroptosis and where to find it?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671998/
https://www.ncbi.nlm.nih.gov/pubmed/34903554
http://dx.doi.org/10.1136/jitc-2021-003430
work_keys_str_mv AT demuynckrobin immunogenicferroptosisandwheretofindit
AT efimovaiuliia immunogenicferroptosisandwheretofindit
AT naessensfaye immunogenicferroptosisandwheretofindit
AT kryskodmitriv immunogenicferroptosisandwheretofindit